{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:32:10Z","timestamp":1780565530957,"version":"3.54.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"DOI":"10.1093\/ckj\/sfw143","type":"journal-article","created":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T23:03:06Z","timestamp":1481929386000},"page":"625-631","source":"Crossref","is-referenced-by-count":26,"title":["Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab"],"prefix":"10.1093","volume":"10","author":[{"given":"Marco","family":"Allinovi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero Lino","family":"Cirami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Caroti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Antognoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Farsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Eugenio","family":"Minetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,2,16]]},"reference":[{"key":"key\n\t\t\t\t20171012004159_sfw143-B1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1200\/JCO.1986.4.2.234","article-title":"Clinical toxicity of interferons in cancer patients: a review","volume":"4","year":"1986","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/08860229109022152","article-title":"Investigations on the subclinical and clinical nephrotoxicity of interferon alpha-2B in patients with myeloproliferative syndromes","volume":"13","year":"1991","journal-title":"Ren Fail"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B3","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2215\/CJN.00860115","article-title":"Drug-induced glomerular disease: direct cellular injury","volume":"10","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","year":"2015","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B5","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the Oklahoma registry and the BloodCenter of Wisconsin","volume":"90","year":"2015","journal-title":"Am J Hematol"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3109\/08860229309054974","article-title":"Hemolytic-uremic syndrome during recombinant alpha-interferon treatment for hairy cell leukemia","volume":"15","year":"1993","journal-title":"Ren Fail"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000045147","article-title":"Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C","volume":"80","year":"1998","journal-title":"Nephron"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/ki.2013.409","article-title":"Interferon-\u03b1-induced thrombotic microangiopathy in patients with chronic myelogenous leukemia","volume":"85","year":"2014","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.msard.2013.12.007","article-title":"Thrombotic microangiopathy in Interferon Beta treated multiple sclerosis patients: review of literature and report of two new cases","volume":"3","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1177\/1352458507076968","article-title":"An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis","volume":"13","year":"2007","journal-title":"Mult Scler"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B11","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00467-009-1188-8","article-title":"Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome","volume":"24","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B12","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s00467-010-1609-8","article-title":"CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by CblC deficiency","volume":"25","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B13","article-title":"CD46-associated atypical hemolytic uremic syndrome with initial focal segmental glomerulosclerosis","year":"2014","journal-title":"CSN"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B14","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/ndt\/gft220","article-title":"Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature","volume":"28","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B15","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B16","first-page":"E30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B17","article-title":"Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: a case report","year":"2016","journal-title":"Rev Med Interne"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/ckj\/sft065","article-title":"Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab","volume":"6","year":"2013","journal-title":"Clin Kidney J"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B19","first-page":"2097","article-title":"Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation \u2013 a case report. Transplant","volume":"43","year":"2011","journal-title":"Proc"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B20","first-page":"125","article-title":"Eculizumab for drug-induced de novo post-transplantation thrombotic microangiopathy: a case report","volume":"83","year":"2015","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B21","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/01.RES.0000182677.89816.38","article-title":"Complement activation in angiotensin II-induced organ damage","volume":"97","year":"2005","journal-title":"Circ Res"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B22","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00415-013-6961-8","article-title":"Hemolytic uremic syndrome: an unusual complication of interferon-\u03b2 treatment in a MS patient","volume":"260","year":"2013","journal-title":"J Neurol"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.5414\/CN106523","article-title":"Thrombotic microangiopathy induced by long-term interferon-\u03b2 therapy for multiple sclerosis: a case report","volume":"76","year":"2011","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B24","first-page":"723","article-title":"Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis","volume":"7","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11255-013-0401-7","article-title":"Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis","volume":"46","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B26","first-page":"340","article-title":"Malignant hypertension and interferon-beta: a case report","year":"2014","journal-title":"J Hum Hypertens"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B27","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1177\/1352458514523692","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon \u03b2","volume":"20","year":"2014","journal-title":"Mult Scler"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B28","article-title":"Case report of thrombotic microangiopathy associated with subcutaneous interferon beta-1a: an emerging complication?","year":"2014","journal-title":"Neurologia"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/1352458513519839","article-title":"Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning","volume":"20","year":"2014","journal-title":"Mult Scler"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B30","first-page":"79","article-title":"Renal thrombotic microangiopathy induced by b-interferon","volume":"4","year":"2011","journal-title":"NDT Plus"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B31","first-page":"97","article-title":"Thrombotic microangiopathy associated with use of interferon-beta","volume":"5","year":"2012","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B32","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1316118","article-title":"Thrombotic microangiopathy associated with interferon beta","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171012004159_sfw143-B33","first-page":"276","article-title":"Thrombotic thrombocytopenic purpura during treatment with interpheron","volume":"128","year":"2007","journal-title":"Med Clin (Barc)"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/10\/5\/625\/20385736\/sfw143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T04:43:14Z","timestamp":1507783394000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ckj\/article\/10\/5\/625\/2999726\/Thrombotic-microangiopathy-induced-by-interferon"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,16]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,2,16]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfw143","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10]]},"published":{"date-parts":[[2017,2,16]]}}}